|
80 and 100 µM
|
48 h
|
Inhibits proliferation and metastasis through suppressing PTHR1
|
U2OS and Saos-2
|
[92]
|
|
25 or 50 µM
|
18 h
|
Suppresses proliferation and migration while inducing apoptosis
|
143B
|
[90]
|
|
25, 50 and 100 µM
|
12 and 24 h
|
Suppresses metastatic lung tumors
|
HOS and MG-63
|
[91]
|
|
10, 25 or 50 µM
|
48 h
|
Induces apoptosis by mitochondrial dysfunction and dephosphorylation of Akt
|
U2OS/MTX300
|
[94]
|
|
–
|
–
|
Reduces mitochondrial membrane potential and release of mitochondrial cytochrome c to cytosol while dephosphorylating Akt
|
U2OS/MTX300
|
[95]
|
|
50, 100 and 200 µM
|
24 h
|
Induces autophagy by the ROS-NUPR1 pathway
|
MG-63
|
[97]
|
|
10, 100, 200, 500 and 1000 µM
|
48 h
|
Induces apoptosis and cell cycle arrest at G(1)/S
|
HOS
|
[96]
|
|
20, 40, 80, 160, 240 and 320 µM
|
48 h
|
Induces apoptosis via a mitochondrial-dependent pathway and reduces cell viability
|
MG-63
|
[93]
|
|
–
|
–
|
Downregulated glucocorticoid receptors in osteosarcoma cells
|
HOS-8603
|
[89]
|
|
5 µM
|
24 h
|
Improves cisplatin sensitivity by miR-217/KRAS axis
|
143B
|
[98]
|
|
50 µM
|
48 h
|
Leads to the alteration in G1/S phase and reduction in cyclin D1 in U2OSPt
|
U2OS and U2OSPt
|
[99]
|
